Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach by Annacarmen Petrizzo et al.
Petrizzo et al. Journal of Translational Medicine 2014, 12:11
http://www.translational-medicine.com/content/12/1/11RESEARCH Open AccessPrediction of individual immune responsiveness
to a candidate vaccine by a systems vaccinology
approach
Annacarmen Petrizzo, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro and Luigi Buonaguro*Abstract
Background: We have previously shown that a candidate idiotype vaccine, based on the IGKV3-20 light chain
protein, is able to induce activation of circulating antigen presenting cells (APCs) in both HCV-positive and
HCV-negative subjects, with production of Th2-type cytokines. In addition, such a candidate idiotype vaccine
induces an early gene expression pattern, characterized by the strong induction of an innate immune response,
and a late pattern, characterized by a prevalent B cell response. Nonetheless, some HCV-positive individuals showed
a complete lack of maturation of circulating APCs with low levels of cytokine production, strongly suggesting the
possible identification of selective impairments in immune response in individual subjects.
Method: Peripheral blood mononuclear cells (PBMCs) were stimulated ex vivo with IGKV3-20 for 24 h and 6 days.
Analysis of the global gene expression profile as well as the cytokine pattern was performed for individual subjects.
Results: The gene expression profile showed a strong agreement with the cytokine pattern. Indeed, the expression
pattern of immune-related genes is highly predictive of the individual immunological phenotype.
Conclusion: The overall results represent a proof of concept, indicating the efficacy of such an ex vivo screening
platform for predicting individual’s responsiveness to an antigen as well as guiding optimization of vaccine design.
Larger cohort study will be needed to validate results observed in the study.
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Hepatitis C virus (HCV) is a Hepacivirus of the Flaviviridae
family, mainly involved in hepatic disorders, including
chronic hepatitis, cirrhosis and hepatocellular carcinoma
(HCC) [1].
HCV has also been recognized as the major etiologic
factor of type II mixed cryoglobulinemia (MC), an auto-
immune disease ultimately leading to B cell non-Hodgkin’s
lymphoma (NHL) in about 10% of MC patients [2-5].
The clonal B cell expansion is characterized by the
production of an Ig molecule expressing a unique com-
bination of antigen-specific sequences, the so called idio-
type (Id). Therefore, the Id can be a suitable target for* Correspondence: l.buonaguro@istitutotumori.na.it
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stated.active, as well as passive immune-therapeutic strategies
to eliminate the B cells driving the tumor [6,7].
In this respect, the IGKV3-20 idiotype has been se-
lected as a potential target of either passive immune
therapy or active vaccine strategy [8].
We have previously reported the results of the effect
of the IGKV3-20 candidate idiotype vaccine on ex vivo
stimulated PBMCs, as experimental platform for evalu-
ation and prediction of responsiveness to vaccination
[9]. IGKV3-20 light chain protein has been shown to in-
duce activation of circulating APCs, i.e., CD14+ mono-
cytes, as well as CD123+ plasmacytoid dendritic cells
(pDCs) and CD11c+ myeloid DCs (mDCs), in both
HCV-positive and HCV-negative healthy control sub-
jects, with production of Th2-type cytokines [9,10]. No
significant difference was observed between results
obtained in human monocyte-derived dendritic cellsl Ltd. This is an Open Access article distributed under the terms of the Creative
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results by us and other groups [11-15].
Moreover, such a candidate idiotype vaccine induces an
early expression pattern, characterized by the induction of
genes related to inflammatory response, and a late pattern,
characterized by the induction of genes related to a B cell
response [10].
Indeed, the Ingenuity Pathways Analysis (IPA) performed
on “early” and “late” up-regulated genes showed a preva-
lence of inflammation and innate immunity-related path-
ways activated at 24 h post-induction, with significant
overlapping between HCV-negative and positive groups,
and a prevalence of “atypical” immune pathways activated
at 6 days post-induction [10].
Nonetheless, some HCV-positive and negative subjects
showed a poor response to the IGKV3-20 protein, with
significant low levels of cytokine production and limited
gene expression pattern.
In this regard, here we describe a systems biology ap-
proach to evaluate the individual responsiveness to the
recombinant IGKV3-20 protein, aiming at identifying a
possible impairment in the immune response and/or
markers of responsiveness to such a specific antigen. In-
deed, the specific effect of the recombinant IGKV3-20
protein has been evaluated ex vivo on human PBMCs of
individual HCV-positive subjects via multiparametric
analyses, including gene expression profiling combined
to multiplex analysis of cytokines.
Materials and methods
Clinical specimens and cell treatment
Overall, samples from six HCV-positive subjects were
analysed for the present study. Samples from five healthy
donors were used as controls. Enrollment of subjects
and treatment of derived human PBMCs have been pre-
viously described [10].
Unsupervised analysis
For the unsupervised analysis a low-stringency filtering
was applied, selecting the genes differentially expressed
in 80% of all experiments with a >3 fold change ratio in
at least one experiment. Hierarchical cluster analysis was
conducted on the selected genes according to Eisen
et al. [16]; differentially expressed genes were visualized
by Treeview and displayed according to the central
method [16,17].
Supervised analysis
Supervised class comparison was performed using BRB
ArrayTool developed at NCI, Biometric Research Branch,
Division of Cancer Treatment and Diagnosis. Two subsets
of genes were explored. The first subset included genes
up-regulated in stimulated (IGKV3-20 treated) PBMCs
compared to non-stimulated (PBS treated) PBMCs after24 h incubation; the second subset included genes up-
regulated in stimulated PBMCs compared to non-
stimulated PBMCs after 6 days incubation.
Class comparison analyses were tested for an univari-
ate significance threshold set at a p-value < 0.001. Gene
clusters identified by the univariate t-test were chal-
lenged with two alternative additional tests, an univariate
permutation test (PT) and a global multivariate PT.
Class comparison and hierarchical clustering were em-
ployed to determine the pattern of response and results are
illustrated as a heat map of significance values. All analyses
were performed using R and Cytoscape (http://www.
cytoscape.org). Gene function was assigned based on
Database for Annotation, Visualization and Integrated
Discovery (DAVID) (http://david.abcc.ncifcrf.gov) and Gene
Ontology (http://www.geneontology.org).
Ingenuity Pathways Analysis (IPA, www.ingenuity.com)
was employed to elucidate the relationship and connec-
tion between differentially expressed genes.
Results
Cytokine pattern induced in circulating APCs
PBMCs obtained from enrolled subjects were incubated
with IGKV3-20 for 24 h and 6 days and, at each time-
point, levels of Th1 (IL-2 and TNF-α) and Th2 (IL-5, IL-
6 and IL-10) cytokines were assessed by ELISA in the
culture supernatant. The results show that the stimula-
tion induces a significant production of both Th1 (TNF-
α) and Th2 cytokines (IL-6 and IL-10) with a prevalent
Th2-biased cytokine pattern, as previously reported [10].
However, specific subjects show levels of cytokine in-
duction significantly far from the mean value, indicating
that differences may be observed in the response elicited
by the antigen (Figure 1).
Indeed, at 24 h post-induction, PBMCs of subject DN
always score at the top for release of TNF-α, IL-6 and
IL-10 (1.7, 1.2 and 2.1 folds over the average, respect-
ively). PBMCs of subject BE show a very similar pattern
for TNF-α and IL-6 (1.8 and 1.2 folds over the average,
respectively), whereas the amount of IL-10 released is
the lowest (0.2 folds over the average). On the contrary,
PBMCs of subjects MML and BD release the lowest
levels of TNF-α and IL-6 (0.4 and 0.8 folds over the
average, respectively) (Figure 1A).
Overall, high levels of IL-6 persist for the 6 days of in-
duction, whereas the induction of IL-10 and, even more,
TNF-α fades away at 6 days (Figure 1B).
Nevertheless, only PBMCs of subject BE (unlike those
of DN) are confirmed to release the highest amount of
TNF-α and IL-6, while PBMCs of subject VA release the
highest amount of IL-10 (Figure 1B). As for the 24 h
time-point, PBMCs of MML are confirmed to release
the lowest amount of all three cytokines (Figure 1B).






































Figure 1 Analysis of cytokine production in supernatant of PBMCs. The cytokine profile induced by IGKV3-20 after 24 h (A) and 6d (B)
incubation was evaluated in supernatant of stimulated PBMCs.
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possibly reflect differences in individual response to the
same antigen after in vivo vaccination.
Identification of immune response pattern to IGKV3-20
at “early” time-point
Subsequently, the gene expression profile of samples from
HCV-positive subjects, previously analyzed as whole
group [10], was evaluated to identify individual patterns
induced by recombinant IGKV3-20 on PBMCs from six
HCV-positive subjects. To this aim, a supervised pair-wise
comparison was performed between stimulated (IGKV3-
20 treated) and non-stimulated (PBS) PBMCs.
The analysis at 24 h identified a clustering confirming
the different response of samples BE (high) and MML
(low) observed in the pattern of cytokine production in-
duced by IGKV3-20 stimulation.
In particular, 394 genes differentially expressed were over-
all identified (201 up-regulated genes and 193 down-
regulated genes) with the strongest gene activation induced
in PBMCs of subject BE and the weakest one induced in
PBMCs of subject MML (Figure 2). The remaining 4
samples showed an intermediate transcriptional pattern,suggesting the possible identification of high vs. weak
responders according to results of simultaneous gene
expression data. A list of modulated genes correlated
with immunology functions is shown in Table 1.
The identified genes were further evaluated, to identify
specific transcription profiles in the individual subjects.
Considering the immune-related genes, heat maps in
Figures 2A and B show a very strong up-regulation of
specific genes mostly in sample BE (e.g., G0S2, VNN3,
CCL18, TNFAIP6, IL-1A, CD80, TRAF1 and SNX9). An
additional set of cytokine and cytokine receptor related
genes, instead, shows a broad activation in all samples
including BE (e.g., IL-1B, IL-6, IL-24, CCL23, CCL20
and IL2RA). The only exception is represented by the
subject MML which shows a very limited pattern of gene
activation and even down-regulation (Figure 2A and B).
Among the genes more strongly activated in BE, the
TNF alpha-induced protein 6 (TNFAIP6), TNF receptor-
associated factor 1 (TRAF1), G0/G1 switch gene 2 (G0S2),
vanin-3 (VNN3) and sorting nexin 9 (SNX9) possibly sug-
gest the activation of a TNF-mediated inflammatory pat-
tern induced by IGKV3-20. Indeed, both TNFAIP6 and
TRAF1 are downstream mediators of TNF signaling [18]
AB
PBS IGKV3-20
Figure 2 Supervised analysis based on IGKV3-20 induction at 24 h. Heat map of gene sets differentially modulated by IGKV3-20 after 24 h.
The heat map in (A) shows several genes whose expression is strongly up-regulated in PBMCs of BE. The heat map in (B) shows several genes
whose expression is down-regulated in PBMCs of MML after IGKV3-20 stimulation. Genes highlighted in yellow are mostly activated in sample BE.
Genes highlighted in blue are activated in all HCV-positive samples, with exception of MML.
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through the activation of the NFKB complex [20]. More-
over, SNX9 promotes internalization of TNFR [21], whereas
VNN3 induction is mediated by Th17/Th1 type cytokines,
including TNF-α [22].
Indeed, the pronounced pro-inflammatory pattern in-
duced by IGKV3-20 in PBMCs of BE is more similar to
the expression profile elicited in samples from healthy
control subjects (Figure 3).
Furthermore, the strong up-regulation of CCL18 and
CD80 molecules confirms the significant activation of
circulating APCs by IGKV3-20 (Figures 2A and 3) [10].
On the other hand, PBMCs of subject MML show down-
regulation of tumor necrosis factor receptor superfamily
member 1B (TNFRSF1B), a mediator of most of the meta-
bolic effects of TNF-α, as well as of interleukin 1 receptor
antagonist (IL1RN), whose expression is implicated in the
modulation of the inflammasome (Figure 2A and B) [23].
This observation suggests the limited pro-inflammatory
effect of TNF-α and IL-1 induced by IGKV3-20 in PBMCs
of MML.Furthermore, C-type lectin domain family 4 member D
(CLEC4D), involved in antigen uptake for processing and
further presentation to T cells, is strongly down-regulated
in PBMCs of MML upon treatment with IGKV3-20, sug-
gesting a possible impairment of the antigen uptake, pro-
cessing and presentation pathway [24,25].
Unexpectedly, CD274 molecule, which has been spec-
ulated to play a major role in suppressing the immune
system during autoimmune disease and disease states,
including hepatitis, is down-regulated by IGKV3-20 in
PBMCs of MML while strongly up-regulated in all the
other HCV-positive samples (Figure 2B) [26].
Identification of immune response pattern to IGKV3-20
at “late” time-point
To evaluate a change in the gene expression pattern
over-time, the transcriptional profiling analysis was per-
formed also after 6 days (“late”) incubation (Figure 4).
The comparison analysis at this late time-point con-
firmed the different clustering of samples BE and MML.
Overall, 105 genes differentially expressed were identified,
Table 1 Immunology genes modulated by IGKV3-20 at 24 h
Gene ID Gene symbol Gene name Gene ID Gene symbol Gene name
7960947 A2M Alpha-2-macroglobulin 8154733 ACO1 Aconitase 1, soluble
8093294 CCR2 Chemokine receptor 2 8071899 ADORA2A Adenosine A2a receptor
7937508 CD151 CD151 molecule 7990818 BCL2A1 BCL2-related protein A1
8133876 CD36 CD36 molecule 8089771 CD80 CD80 molecule
7953428 CD4 CD4 molecule 7898655 CDA Cytidine deaminase
8115147 CD74 MHC, class II invariant chain 8042942 HK2 Hexokinase 2
8082035 CD86 CD86 molecule 8025601 ICAM1 Intercellular adhesion mol. 1
7966089 CMKLR1 Chemokine-like receptor 1 8097553 IL15 Interleukin 15
8115076 CSF1R Colonystimul. factor 1 recep. 8054712 IL1A Interleukin 1, alpha
8065403 CST3 Cystatin C 8054722 IL1B Interleukin 1, beta
8166730 CYBB Cytochrome b-245, beta polypeptide 8044574 IL1RN Interleukin 1 receptor antagonist
8108370 EGR1 Early growth response 1 7931914 IL2RA Interleukin 2 receptor, alpha
7985268 FAH Fumarylacetoacetate hydrolase 8131803 IL6 Interleukin 6
816502 FBP1 Fructose-1,6-bisphosphatase 1 8077786 IRAK2 IL1 receptor-ass. kinase 2
8165011 FCN1 Ficolin 1 8035351 JAK3 Janus kinase 3
8058765 FN1 Fibronectin 1 7973336 MMP14 Matrix metallpeptidase 14
7913694 FUCA1 Fucosidase, alpha-L-1, tissue 7951217 MMP7 Matrix metallopeptidase 7
8129974 FUCA2 Fucosidase, alpha-L-2, plasma 8172220 NDP Norrie disease
8163908 GGTA1 Glycoprotein, alpha-
galactosyltransferase 1 pseudogene
7930074 NFKB2 Nuclear factor of kappa light polypeptide gene enhancer
in B-cells 2 (p49/p100)
8180346 GPX1 Glutathione peroxidase 1 8075316 OSM Oncostatin M
8157582 GSN Gelsonlin 8062927 PI3 Peptidase inhibitor 3
7941936 GSTP1 Glutathione S-transferase pi 1 8150509 PLAT Plasmin. activator, tissue
8140556 HGF Hepatocyte growth factor 8037775 PTGIR Prostagladin I2 receptor (IP)
8180086 HLA-DMA MHC, class II, DM alpha 7922976 PTGS2 Prostag-endoperox synthase 2
8180078 HLA-DMB MHC, class II, DM beta 7977786 SLC7A7 Solute carrier fam 7, memb 7
8180100 HLA-DPA1 MHC, class II, DP alpha 1 8130556 SOD2 Superoxide dismutase 2
8179519 HLA-DPB1 MHC, class II, DP beta 1 8066214 TGM2 Transglutaminase 2
8179481 HLA-DRA MHC, class II, DR alpha 8045688 TNFAIP6 TNF, alpha-induced protein 6
8058552 IDH1 Isocitrate dehydrognase 1 7897877 TNFRSF1B TNF receptor superfam, 1B
7942300 IL18BP Interleukin 18 binding protein 7912145 TNFRSF9 TNF rec. superfam, memb 9
8070826 ITGB2 Intergrin, beta 2 8163825 TRAF1 TNF receptor-assoc. factor 1
8090162 ITGB5 Integrin, beta 5
7957023 LYZ Lysozyme
8127854 ME1 Malic enzyme 1
7926451 MRC1 Mannose receptor, C type 1
8149448 MSR1 Macrophage scavenger recept 1
8076403 NAGA N-acetylgalactosaminidase, a
8072744 NCF4 Neutrophil cytosolic factor 4
8157650 PTGS1 Prostag-endoperoxsynthase 1
7920271 S100A4 S100 calcium binding protein A4
8136557 TBXAS1 Thromboxane A synthase 1
8157524 TLR4 Toll-like receptor 4
7924499 TLR5 Toll-like receptor 5
Down-regulated (left) and up-regulated (right) genes.
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IGKV3-20 stimulation. A list of modulated genes corre-
lated with immunology functions is shown in Table 2. The
number of differentially expressed genes at late time-point
is drastically reduced compared to the early time-point,
but it is still indicative of a late modulation of the immune
response by IGKV3-20.
Among the up-regulated genes CD300E, CLEC4D and
FCAR are mostly activated in sample BE (Figure 4B). More-
over, several members of the leukocyte immunoglobulin-
like receptor (LILR) family (i.e., LILRA1, LILRA3 and
LILRA5) are activated, indicating a relevant role for such
innate immune receptors, expressed on monocytes and B
cells, in the response elicited by the IGKV3-20 (Figure 4A
and B)[27].
Even at 6 days the expression pattern induced by
IGKV3-20 in PBMCs of BE strongly resembles the
expression profile elicited by the same antigen in a
cohort of healthy control subjects, as indicated by the
dendrogram at the top of matrix in Figure 5.
On the other hand, immune genes such as LILRA3,
CXCL13, CRLF2 and CD82 are even down-regulated in
sample MML, suggesting the inefficient delivery of co-
stimulatory signals for the T cell receptor (TCR)/CD3
pathway for such a subject (Figure 4A) [28].
Identification of unique immune signatures in PBMCs of
BE and MML
A subsequent supervised analysis was performed indivi-
dually comparing sample BE or MML to all the otherFigure 3 Supervised analysis based on IGKV3-20 induction at 24 h. He
positive (pink dots) and HCV-negative healthy control (blue dots) subjects. The dendrogsamples, and such analysis included all genes modulated by
IGKV3-20 without subtracting the basal expression pat-
terns (i.e., PBS).
In regards to PBMCs of subject BE, overall 102 differ-
entially expressed genes were identified at 24 h post
stimulation, of which 62 up-regulated and 40 down-
regulated genes (data not shown).
Among the up-regulated genes, several were identified as
immunology genes and the resulting immunology network
was visualized using Cytoscape (http://www.cytoscape.org)
(Figure 6A).
At 6 days post stimulation, overall 617 differentially
expressed genes were identified, of which 349 up-
regulated and 268 down-regulated genes (data not shown).
Interestingly, a unique gene signature was identified, char-
acterized by the up-regulation of Th1 cytokine (i.e., TNF
and IFNγ) and cytokine receptor (i.e., IL2RB, IL18R1 and
IL12RB2) genes, as well as high-affinity Fc-gamma receptor
genes (i.e., FCGR1A and FCGR1B) (Figure 6B). All these
genes contribute to the inflammatory response, promoting
proliferation of natural killer (NK) cells, as well as T-cells of
the Th1 phenotype, strongly suggesting a loop of specific
activation of the IFNγ signaling [29], confirmed also by the
IPA analysis (Figure 7).
On the other hand, in PBMCs of subject MML, the ana-
lysis identified overall 479 differentially expressed genes at
24 h, whereas 122 genes were differentially expressed at 6
days (data not shown). However, marker genes of the im-
mune response were not identified up-regulated and most
of the identified genes were not even annotated.at map of gene sets differentially modulated by IGKV3-20 after 24 h, in HCV-
ram at the top of the matrix indicates the degree of similarity between samples.
BA
PBS IGKV3-20
Figure 4 Supervised analysis based on IGKV3-20 induction at 6d. Heat map of gene sets differentially modulated by IGKV3-20 after 6 days.
The heat map in (A) shows several genes whose expression is down-regulated in PBMCs of MML. The heat map in (B) shows several genes
whose expression is strongly up-regulated in PBMCs of BE.
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genes (i.e., KLRD1, KLRB1, KLRF1, KIR2DL4, KIR2DS1)
were found down-regulated (Figure 6C and D), suggesting
a possible impairment of the NK cell function in such a
subject [30].Table 2 Immunology genes modulated by IGKV3-20 at 6 days
Gene ID Gene symbol Gene name G
7960947 A2M Alpha-2-macroglobulin 8
8127854 ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic 8







Down-regulated (left) and up-regulated (right) genes.The overall results suggest the identification of mo-
lecular markers of individual response to a specific
antigen, which could represent a platform for the iden-
tification of common predictive signatures of response
to vaccination.ene ID Gene symbol Gene name
093294 CCR2 Chemokine receptor 2
063386 CEBPB CCAAT/enhancer binding protein (C/EBP), beta
031374 FCAR Fc fragment of IgA, receptor for
921873 FCGR3A
Fc fragment of IgG, low affinity
Illa, receptor (CD16a)
038899 FPR1 Formly peptide receptor 1
042942 HK2 Hexokinase 2
047086 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1)
920244 S100A8 S100 calcium binding protein A8
982597 THBS1 Thrombospodin 1
Figure 5 Supervised analysis based on IGKV3-20 induction at 6d. Heat map of gene sets differentially modulated by IGKV3-20 after 6 days in
HCV-positive (pink dots) and HCV-negative healthy control (blue dots) subjects. The dendrogram at the top of the matrix indicates the degree of
similarity between samples.
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A major challenge in vaccinology is to predict vaccine
efficacy [31-33]. Here, we used a multiparametric sys-
tems biology approach to identify gene signatures pre-
dictive of an immune response, using an experimental
platform based on PBMCs from 6 HCV-positive subjects
stimulated ex vivo with the IGKV3-20 light-chain pro-
tein, as candidate idiotype vaccine.
The cytokine pattern induced by IGKV3-20 was
assessed by ELISA in culture supernatant of stimulated
PBMCs, after 24 h or 6 days of incubation (Figure 1).
The results show that the stimulation induces an over-
all significant production of both Th1 (TNF-α) and Th2
cytokines (IL-6 and IL-10), with a prevalence of the
latters. However, specific samples consistently show
very different levels of TNF-α and IL-6 production,
which are highest for samples BE and DN and lowest
for sample MML. These results, although based on a
small cohort, indicate a significant difference in the
individual response to the same antigen and, in particu-
lar, suggest that subject BE is characterized by a relevant
pro-inflammatory pattern with the highest levels of
IL-6 and TNF-α and the lowest level of the anti-
inflammatory IL-10 (Figure 1).
The global gene expression profile of PBMCs stimu-
lated with IGKV3-20 for 24 h and 6 days confirmed such
strong differences between BE and MML.
Indeed, in agreement with the cytokine expression pat-
tern, the sample from subject BE shows the highest numberof strongly activated genes, whereas the sample from
subject MML shows the weakest transcriptional profile
(Figures 2 and 4).
In particular, considering immune-related genes up-
regulated at 24 h, the activation of a TNF-mediated in-
flammatory pattern in subject BE induced by IGKV3-20
is strongly suggested (Figure 2A). Moreover, the up-
regulation of CCL18 and CD80 molecules suggests a
significant activation of circulating APCs in this subject
(Figure 2A). On the contrary, several immune-related
genes are even down-regulated in PBMCs of MML, sugges-
ting a possible impaired activation of a pro-inflammatory
and/or immune response by the antigen.
The strong difference in transcriptional profile of
immune-related genes between subjects BE and MML is
confirmed also after 6 days of incubation with IGKV3-20
(Figure 4).
Indeed, BE shows the gene activation of several mem-
bers of the LILR (i.e., LILRA1, LILRA3 and LILRA5)
family of immunoreceptors, as well as CD300E, CLEC4D
and FCAR (Figure 4A and B).
More importantly, the supervised analysis performed
on the pool of genes modulated by IGKV3-20, with-
out subtracting PBS pattern, identified a late tran-
scriptional profile characterized by the up-regulation
of TNF, IFNγ, IL2RB, IL18R1, IL12RB2, FCGR1A and
FCGR1B genes (Figure 6B), which is unique for sub-
ject BE and suggestive of a possible Th1-polarization
of the immune response.
A B
C D
Figure 6 Unique immune signatures induced in PBMCs of BE and MML. Cytoscape analysis of immunology genes modulated by IGKV3-20
in PBMCs of BE at 24 h (A) and 6d (B). Cytoscape analysis of immunology genes and killer cell receptor genes modulated by IGKV3-20 in PBMCs
of MML at 24 h (C) and 6d (D).
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induced by IGKV3-20 in PBMCs of BE strongly resembles
the expression profile elicited by the same antigen in a co-
hort of HCV-negative healthy control subjects, as indicated
in Figures 3 and 5.
On the contrary, a global down-regulation of immune
genes such as killer cell receptor genes in PBMCs of MML
may even suggest the inefficient establishment of NK cell-
mediated innate immune response to the candidate idio-
type vaccine.
Overall, the multiparametric analysis performed on
PBMCs loaded ex vivo with the IGKV3-20 candidate id-
iotypic vaccine shows that the identification of specificgene transcriptional patterns to confirm differences in
the immune response evaluated by means of different
parameters (e.g., cytokine profile) is feasible.
Indeed, subjects BE and MML are clearly different re-
gardless the parameters used to analyze the ex vivo effect
of the IGKV3-20 on their PBMCs, suggesting a possible
marked diversity of their responsiveness to such an anti-
gen if administered in vivo.
In conclusion, the present study represents a proof of con-
cept and larger cohort studies will be needed to validate the
results. Nevertheless, our results strongly suggest that our
ex vivo screening platform is potentially useful to identify
“proficient” prediction markers of individual responsiveness
Figure 7 Ingenuity pathways analysis. IFNγ signaling pathway uniquely activated in PBMCs of subject BE after 6 days stimulation with IGKV3-20.
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proteins, DNA), as well as to guide optimization of vaccine
design.
Moreover, systems biology approaches not only allows
the scrutiny of a global picture of vaccine-induced im-
mune effect but can be also used to uncover new corre-
lates of vaccine efficacy [34].
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